Cheson BD, Bartlett NL, LaPlant B, et al. - Among untreated older patients suffering from Hodgkin lymphoma or in younger patients regarded as unsuitable for standard ABVD (ie, doxorubicin, bleomycin, vinblastine, and dacarbazine) therapy, researchers undertook this multicentre, single-arm, phase 2 trial to assess the safety as well as the efficacy of brentuximab vedotin and nivolumab. This inquiry was conducted at eight cancer centres in the US. Eligible patients were administered brentuximab vedotin at 1.8 mg/kg (dose cap at 180 mg) and nivolumab at 3 mg/kg both intravenously every 21 days for 8 cycles. Findings showed activity of brentuximab vedotin plus nivolumab in older patients with previously untreated Hodgkin lymphoma with comorbidities, although the prespecified activity criteria was not met in this trial. In most of the older patients, the good tolerability of the regimen was seen.